Uncategorized

iCUBATE® EARNS FDA CLEARANCE FOR LATEST ASSAY

NOW PROVIDING U.S. CLINICAL LABORATORIES A COMPREHENSIVE DETECTION SOLUTION IN THE BATTLE AGAINST BLOODSTREAM INFECTIONS AND SUBSEQUENT SEPSIS   HUNTSVILLE, AL, July 12, 2019 – iCubate®, provider of accurate and affordable syndromic test systems generating actionable results to healthcare providers, announced today that it has obtained U.S. Food and Drug...

Read more

iCubate® Announces CE IVD Mark for iC-GN Assay™

HUNTSVILLE, AL, June 27, 2019 – iCubate® , a provider of molecular solutions for the rapid diagnosis of infectious diseases, announced the securing of CE IVD Marking for the company’s latest assay, the “iC-GN Assay™”. The iC-GN Assay is an in vitro diagnostic test for the detection and identification of...

Read more

CEO Corner – ASM Microbe 2019

SAN FRANCISCO, CA, June 26, 2019 – It was our privilege to be a part of ASM Microbe this year! We enjoyed seeing colleagues, meeting new friends, networking and learning more about the leading edge work in the ASM community. From the feedback I received, many of you were also...

Read more

CEO Corner

SAN FRANCISCO, CA, June 13, 2019 – iCubate is proud to be a part of ASM Microbe 2019. Many of us will be on site at the Moscone Center in San Francisco for this outstanding scientific conference. At ASM Microbe 2019, there are many ways to learn why iCubate is...

Read more

iCubate, Wondfo Biotech Form Chinese JV to Develop MDx Assays

NEW YORK (GenomeWeb) — iCubate said today that it has formed a joint venture with Wondfo Biotech to commercialize infectious disease molecular diagnostics in China. The joint venture — called Wondfo-iCubate Biotech — will develop assays using iCubate’s amplicon-rescued multiplex PCR (arm-PCR) technology, which the company has said can amplify...

Read more

iCubate® receives the 2019 NAITA Global Trade Award

HUNTSVILLE, AL, April 19, 2019 – The North Alabama International Trade Association announced Thursday that Huntsville molecular diagnostic firm iCubate® received the 2019 NAITA Global Trade Award at NAITA’s 36th Annual World Trade Day Luncheon. With international sales leading the way to increased market opportunities, iCubate® provides rapid, accurate and...

Read more

iCubate® and Wondfo Biotech form joint venture to provide high performance infectious disease molecular diagnostics to China

HUNTSVILLE, AL – iCubate®, Inc. and Guangzhou Wondfo Biotechnology Co., Ltd. (Wondfo) formed the joint venture company, Guangzhou Wondfo iCubate Biotechnology Co., Ltd (Wondfo-iCubate Biotech). The strategic purpose of Wondfo-iCubate Biotech is to couple iCubate’s technology and portfolio of products with Wondfo’s commercial strength in multiple in vitro diagnostic areas and...

Read more

iCubate® Presents New Product Information to South Central Association of Clinical Microbiology

HUNTSVILLE, AL, March 21, 2019 – iCubate®, a provider of molecular diagnostic solutions for infectious disease detection, hosted a panel presentation at the South Central Association of Clinical Microbiology (SCACM) meeting in Sandusky, Ohio. The presentation titled, “A Clinical Perspective of the iCubate® Solution for Bloodstream Infection” was led by...

Read more